RT Journal
A1 Gugelmann HM, Perrone J
T1 PRescription drug monitoring programs—reply
JF JAMA
JO JAMA
YR 2012
FD March 7
VO 307
IS 9
SP 912
OP 913
DO 10.1001/jama.307.9.912-c
UL http://dx.doi.org/10.1001/jama.307.9.912-c
AB 
Like Yokell et al, we have also noted—both in our own clinical practice and in that of colleagues—that real-time access to prescription databases for health professionals facilitates a patient-centered approach to addressing opioid abuse. In addition, we have encountered physicians managing chronic opioid therapy who are more comfortable checking a prescription monitoring program report than mandating urine drug screening, which requires awkward patient confrontation and can result in disruption of the patient-physician alliance.1